Study title: Longo-D-L, Russo-A, Duffey-P-L, Hubbard-S-M, Glatstein-E, Hill-J-B, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD. Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, {J-Clin-Oncol}, Feb 1991, vol. 9, no. 2, p. 227-35, ISSN: 0732-183X.Longo-D-L, Russo-A, Duffey-P-L, Hubbard-S-M, Glatstein-E, Hill-J-B, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD. Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, {J-Clin-Oncol...
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Neoplasms [C04] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: PROCARBAZINE | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |